The estimated Net Worth of Thomas Patrick Kelly is at least $4.45 million dollars as of 15 February 2024. Mr. Kelly owns over 3,010 units of Deciphera Pharmaceuticals Inc stock worth over $2,056,157 and over the last 17 years he sold DCPH stock worth over $305,555. In addition, he makes $2,086,680 as Chief Financial Officer, Executive Vice President et Treasurer at Deciphera Pharmaceuticals Inc.
Sign up
Mr. Kelly DCPH stock SEC Form 4 insiders trading
Thomas has made over 25 trades of the Deciphera Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 3,010 units of DCPH stock worth $47,016 on 15 February 2024.
The largest trade he's ever made was exercising 40,000 units of Deciphera Pharmaceuticals Inc stock on 23 December 2019 worth over $75,600. On average, Thomas trades about 4,401 units every 177 days since 2007. As of 15 February 2024 he still owns at least 80,350 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kelly stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Kelly biography
Thomas J. Kelly serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. Mr. Kelly has served as our Executive Vice President, Chief Financial Officer and Treasurer since January 2019 and as our Chief Financial Officer and Treasurer since February 2015. Prior to joining Deciphera, Mr. Kelly served as Chief Financial Officer of AdvanDx, Inc., a private molecular diagnostics company, from 2012 to 2014. Prior to joining AdvanDx, Mr. Kelly served as chief financial officer for various public and private life science companies, including deCODE genetics, Inc. from 2010 to 2011 and Critical Therapeutics, Inc. from 2007 to 2008. Prior to joining Critical Therapeutics, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams and was an attorney in the corporate and securities group of Foley, Hoag and Elliot, LLP. Mr. Kelly holds a J.D. with honors degree from the University of Chicago Law School and a B.S. in Foreign Services degree cum laude from the Georgetown University School of Foreign Service.
What is the salary of Thomas Kelly?
As the Chief Financial Officer, Executive Vice President et Treasurer of Deciphera Pharmaceuticals Inc, the total compensation of Thomas Kelly at Deciphera Pharmaceuticals Inc is $2,086,680. There are 3 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
How old is Thomas Kelly?
Thomas Kelly is 49, he's been the Chief Financial Officer, Executive Vice President et Treasurer of Deciphera Pharmaceuticals Inc since 2019. There are 17 older and 2 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
What's Thomas Kelly's mailing address?
Thomas's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Insiders trading at Deciphera Pharmaceuticals Inc
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar et Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
What does Deciphera Pharmaceuticals Inc do?
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
What does Deciphera Pharmaceuticals Inc's logo look like?
Complete history of Mr. Kelly stock trades at Deciphera Pharmaceuticals Inc et Cortexyme Inc
Deciphera Pharmaceuticals Inc executives and stock owners
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Steven Hoerter,
President, Chief Executive Officer, Director -
Michael Taylor,
Director -
Matthew Sherman,
Executive Vice President, Chief Medical Officer -
Thomas Kelly,
Chief Financial Officer, Executive Vice President, Treasurer -
Steven L. Hoerter,
Pres, CEO & Director -
Daniel Flynn,
Founder, Executive Vice President, Chief Scientific Officer -
Dr. Matthew L. Sherman,
Exec. VP & Chief Medical Officer -
Ron Squarer,
Independent Director -
Frank Friedman,
Independent Director -
Thomas Patrick Kelly J.D.,
Exec. VP, CFO & Treasurer -
Dr. Matthew L. Sherman M.D.,
Exec. VP & Chief Medical Officer -
Dr. Daniel L. Flynn,
Exec. VP, Chief Scientific Officer & Founder -
Daniel C. Martin,
Sr. VP & Chief Commercial Officer -
Dr. Stephen B. Ruddy Ph.D.,
Sr. VP & Chief Technical Officer -
Susan Kelley,
Independent Director -
James Bristol,
Independent Chairman of the Board -
Edward Benz,
Independent Director -
Patricia Allen,
Independent Director -
Dennis Walsh,
Independent Director -
John Martin,
Independent Director -
Melissa Forst,
IR Contact Officer -
Lisa Amaya Price,
Sr. VP & Chief HR Officer -
Jennifer Larson,
Sr. VP of Fin. & Investor Relations -
Margarida Duarte,
Sr. VP & Head of International -
Jama Pitman,
Sr. VP of Regulatory, Quality & Portfolio Management -
Jeffrey M. Held J.D.,
Sr. VP & Gen. Counsel -
Jennifer Robinson,
VP of Investor Relations -
Dashyant Dhanak,
EVP & Chief Scientific Officer -
Leaf Venture Management Iii...,
-
Liam Ratcliffe,
Director -
Associates Llc Brightstar,
10% owner -
Christopher John Morl,
Chief Business Officer -
Michael Jay Ross,
Director -
Oliver Rosen,
Chief Medical Officer -
Stephen B. Ruddy,
Chief Technical Officer -
Daniel C. Martin,
Chief Commercial Officer -
Jama Pitman,
SVP, Chief Development Officer